Abstracts tagged "Gout and uric acid"

Abstract Number: 1628 • 2012 ACR/ARHP Annual Meeting
Epistatic Interaction Between Solute Carrier 2A9 Genotype and Sugar-Sweetened Beverage Consumption in the Determination of Gout Risk
Tony R. Merriman¹, Nicola Dalbeth², Peter J. Gow³, Andrew Harrison⁴, John Highton⁵, Peter B. B. Jones⁶, Lisa K. Stamp⁷, Murray Cadzow⁸, Marilyn E. Merriman¹, Ruth Topless¹, Michael A. Black⁸, Amanda Phipps-Green¹ and Caitlin M. Batt⁸, ¹Department of Biochemistry, University of Otago, Dunedin, New Zealand, ²Medicine, University of Auckland, Auckland, New Zealand, ³Rheumatology Dept, Middlemore Hospital, Auckland, New Zealand, ⁴Rheumatology Unit, Hutt Hospital, Lower Hutt, New Zealand, ⁵Dept of Medicine, Univ of Otago Med Sch, Dunedin, New Zealand, ⁶Medicine, Waikato Clinical School, Waikato Hospital, Hamilton, New Zealand, ⁷Department of Medicine, University of Otago, Christchurch, Christchurch, New Zealand, ⁸University of Otago, Dunedin, New Zealand
Background/Purpose: Consumption of drinks sweetened with sugar or high fructose corn syrup increases both serum urate levels and the risk for gout. SLC2A9 encodes a…
Abstract Number: 1630 • 2012 ACR/ARHP Annual Meeting
Genetic Variants of Serum Uric Acid and Gout: An Analysis of > 170,000 Individuals
Hyon Choi¹, Robert M. Plenge², Anna Köttgen³, Veronique Vitart⁴, Murielle Bochud⁵, Christian Gieger⁶, Mark Caulfield⁷, Marina Ciullo⁸, Eva Albrecht⁶, Alexander Teumer⁹, Gary Curhan¹⁰, Jan Krumsiek¹¹, Conall O'Seaghdha¹², Caroline Fox¹³ and The Global Urate Genetics Consortium (GUGC)¹⁴, ¹Section of Rheumatology and the Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, ²Division of Rheumatology, Immunology and Allergy and Division of Genetics, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ³Renal Division, Freiburg University Hospital, Freiburg, Germany, ⁴Institute of Genetics and Molecular Medicine, Western General Hospital, Edinburgh, United Kingdom, ⁵Institute of Social and Preventive Medicine (IUMSP), Lausanne University Hospital, Switzerland, ⁶German Research Center for Environmental Health, Neuherberg, Germany, ⁷William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, ⁸Institute of Genetics and Biophysics, "A. Buzzati-Traverso", Italy, ⁹Interfaculty Institute for Genetics and Functional Genomics, Ernst-Moritz-Arndt- University Greifswald, Greifswald, Germany, ¹⁰German Research Center for Environmental Health, Harvard Medical School, Boston, MA, ¹¹Institute of Bioinformatics and Systems Biology, German Research Center for Environmental Health, Neuherberg, Germany, ¹²German Research Center for Environmental Health, NHLBI's Framingham Heart Study and Center for Population Studies,, Neuherberg, ¹³Institute of Genetics and Biophysics, NHLBI's Framingham Heart Study and Center for Population Studies, Framingham, MA, ¹⁴Section of Rheumatology and the Clinical Epidemiology Unit, Boston University of School of Medicine, Boston, MA
Background/Purpose: Gout is a common and excruciatingly painful inflammatory arthritis caused by hyperuricemia. In addition to various lifestyle risk factors, a substantial genetic predisposition to…
Abstract Number: 818 • 2012 ACR/ARHP Annual Meeting
Levotofisopam Has Uricosuric Activity and Reduces Serum Urate Levels in Patients with Gout
Robert J. Noveck¹, Zongyao Wang¹, Ann Forsthoefel¹, Kristina Sigmon², Pauliana C. Hall³, John C. Keogh⁴ and John S. Sundy², ¹Duke Clinical Research Unit, Duke University Medical Center, Durham, NC, ²Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, ³PCH Integrated Regulatory Services, Inc., Laguna Niguel, CA, ⁴Keogh Medical Writing, Philadelphia, PA
Background/Purpose: The investigational new drug levotofisopam is the S-enantiomer of racemic tofisopam, a 2,3-benzodiazepine derivative approved in over 20 countries outside the US for treatment…
Abstract Number: 161 • 2012 ACR/ARHP Annual Meeting
Increased Serum Uric Acid: Consequence or Cause of Increased Cardiovascular Risk
Inger L. Meek¹, Harald E. Vonkeman² and Mart A.F.J. van de Laar³, ¹Rheumatology & Clinical Immunology, Rheumatology Center Twente, Medisch Spectrum Twente & Twente University, Enschede, Netherlands, ²Rheumatology Center Twente, Medisch Spectrum Twente & Twente University, Enschede, Netherlands, ³Rheumatology, Medisch Spectrum Twente & University of Twente, Enschede, Netherlands
Background/Purpose: Reports on cardiovascular (CV) disease in hyperuricemia and gout show conflicting results. Some studies show hyperuricemia to be an independent risk factor for CV…
Abstract Number: 138 • 2012 ACR/ARHP Annual Meeting
Evaluating Appropriate Use of Prophylactic Colchicine and Urate Lowering Therapy in Gout
Michael George¹, Sally W. Pullman-Mooar² and H. Ralph Schumacher³, ¹Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, ²Rheumatology, University of Pennsylvania and Philadelphia Veterans Hospital, Philadelphia, PA, ³Department of Medicine, University of Pennsylvania and VA Medical Center, Philadelphia, PA
Background/Purpose: Colchicine is recommended to prevent gout flares in patients initiating and increasing uric acid lowering therapy until serum uric acid is ≤ 6 mg/dL.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].